Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A trans-regional survey
source: American Journal of Hematology
year: 2016
authors: Cronin R M, Hankins J S, Adams-Graves P, Thompson A A, Kalinyak K, Byrd J, McClain B, Kassim A, DeBaun M, Treadwell M
summary/abstract:Patient recruitment into sickle cell disease (SCD) clinical trials has not always been robust, leading to delayed results or even failure to trial completion. Disparities impacting participation in research include race, lower socioeconomic status and lower health literacy. We sought to extend previous research by surveying adults with SCD and parents of children with SCD across geographically diverse regions in the U.S. We hypothesized that demographic variables such as lower income and education would present barriers to interest in research participation, as would psychosocial variables (depression symptoms and lower health literacy). We also evaluated patient/family preferences in use of technology for being contacted about research.
We surveyed a convenience sample of adults, and parents of children with SCD, all genotypes. We used the Mid-South Clinical Data Research Network survey to gather socio-demographic information, depression symptoms (Patient Health Questionnaire—PHQ-2) and health literacy (Brief Health Literacy Screening). We assessed participant interest in varying research types and asked if they would want to be contacted for research using electronic communication—e-mail, text messaging, and social media—as well as traditional face-to-face conversations in clinic or phone calls. We examined differences in demographic and psychosocial variables between participants who responded they were interested in each research type versus those that were not (study outcome) using Fisher’s exact and Wilcoxon tests, and created logistic regression models for each research type, analyses performed in R version 3.2.2.
organization: Vanderbilt University Medical Center, Nashville, Tennessee; St Jude Children's Research Hospital, Memphis, Tennessee; University of Tennessee Health Science Center, Memphis, Tennessee; Northwestern University, Chicago, Illinois; Cincinnati Children's Hospital, Cincinnati, Ohio; UCSF Benioff Children's Hospital Oakland, Oakland, CaliforniaDOI: 10.1002/ajh.24483
read more full text
Related Content
-
Sancilio Pharmaceuticals Company, Inc. Announces Completion of Enrollment in the SCOT Trial in Pediatric Patients Wi...Sancilio Pharmaceuticals Company, Inc. (...
-
California Institute For Regenerative Medicine Awards City Of Hope $5.74 Million For Severe Sickle Cell Disease Clin...The California Institute for Regenerativ...
-
Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized tr...Clinical and preclinical data demonstrat...
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
Successful utilization of an electronic pain diary in a multinational phase 3 interventional study in pediatric sick...Background: Patients with sickle cell a...
-
Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCDThe Green Park Collaborative (GPC) is wo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.